Abstract:During the last thirty years since the discovery of endothelin-1, the therapeutic strategy that has evolved in the clinic, mainly in the treatment of pulmonary arterial hypertension, is to block the action of the peptide either at the ET(A) subtype or both receptors using orally active small molecule antagonists. Recently, there has been a rapid expansion in research targeting ET receptors using chemical entities other than small molecules, particularly monoclonal antibody antagonists and selective peptide agonists and antagonists. While usually sacrificing oral bio-availability, these compounds have other therapeutic advantages with the potential to considerably expand drug targets in the endothelin pathway and extend treatment to other pathophysiological conditions. Where the small molecule approach has been retained, a novel strategy to combine two vasoconstrictor targets, the angiotensin AT(1) receptor as well as the ET(A) receptor in the dual antagonist sparsentan has been developed. A second emerging strategy is to combine drugs that have two different targets, the ET(A) antagonist ambrisentan with the phosphodiesterase inhibitor tadalafil, to improve the treatment of pulmonary arterial hypertension. The solving of the crystal structure of the ET(B) receptor has the potential to identify allosteric binding sites for novel ligands. A further key advance is the experimental validation of a single nucleotide polymorphism that has genome wide significance in five vascular diseases and that significantly increases the amount of big endothelin-1 precursor in the plasma. This observation provides a rationale for testing this single nucleotide polymorphism to stratify patients for allocation to treatment with endothelin agents and highlights the potential to use personalized precision medicine in the endothelin field.

Development of Novel Dual Angiotesin II and Endothelin Receptor Antagonists

Development of Novel Dual Angiotesin Ⅱ and Endothelin Receptor Antagonists

Pharmacophore Modeling of Dual Angiotensin II and Endothelin A Receptor Antagonists.

Structural Insights into Angiotensin Receptor Signaling Modulation by Balanced and Biased Agonists.

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Structural Insights into Ligand Recognition and Activation of Angiotensin Receptors.

Design of Novel Thiazole Bearing Pyrazole Derivatives and Their Dual Activities as ACE Inhibitors and Calcium Channel Blockers in Cardiovascular Disease

Synthesis and in Vitro Evaluation of Ambrisentan Analogues As Potential Endothelin Receptor Antagonists.

Small molecule angiotensin converting enzyme inhibitors: A medicinal chemistry perspective

Synthesis and Biological Evaluation of 4 '-[(Benzimidazole-1-yl)methyl]biphenyl-2-sulfonamide Derivatives As Dual Angiotensin Ii/Endothelin A Receptor Antagonists

Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure

Current and future strategies for targeting the endothelin pathway in cardiovascular disease

Synthesis and biological activity evaluation of AT1 angiotensin II receptor antagonists of dibenzimidazoles with N-phenyl-1 H-pyrrole

New therapeutic targets in hypertension

Structural basis of antagonist selectivity in endothelin receptors

Dual Inhibitors of Angiotensin Converting Enzyme and Neutral Endopeptidase

Research and Development of the New Drugs Acting on Angiotensin II Receptor

Implications of β-Arrestin biased signaling by angiotensin II type 1 receptor for cardiovascular drug discovery and therapeutics

New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine

Research and Development of Aldosterone Inhibitors

Ligand Based Drug Designing of Molecular Target PPARγ/AT1R Through CDOCKER and ADMET Prediction